Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEM-iSMART A: Decitabine, Venetoclax, and Navitoclax in Pediatric R/R ALL/LBL
NCT05740449Phase 2Withdrawn
- Sponsor
- Princess Máxima Center for Pediatric Oncology
- Start
- Oct 2023
- Primary completion
- Oct 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of navitoclax in acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL), sponsored by Princess Máxima Center for Pediatric Oncology. Planned start Oct 2023; status: withdrawn.
02
Drugs
navitoclax
03
Conditions
acute lymphoblastic leukemia (ALL)lymphoblastic lymphoma (LL)
Beyond the preview
Go deeper on NCT05740449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05740449.